search
Back to results

CareSuperb COVID-19 Antigen Test Usability

Primary Purpose

COVID-19

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CareSuperb COVID-19 Antigen Home Test Kit
Sponsored by
AccessBio, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COVID-19

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria: An Institutional Review Board (IRB) approved informed consent / assent, if applicable, is signed and dated prior to any study-related activities. Male and female subjects 2 years of age and older. Subject is willing to provide a self-collected nasal swab sample. (If the subject is under the age of 14, an adult lay-user will collect the sample.) Subject agrees to complete all aspects of the study. Exclusion criteria: Subject has a visual impairment that cannot be restored with glasses or contact lenses. Subject has prior medical or laboratory training. Subject uses home diagnostics, e.g., glucose meters, HIV tests. Subject has prior knowledge of their current COVID-19 infection status.

Sites / Locations

  • L&A Morales Healthcare Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

individuals ages 14 years and older

individuals aged 2 to 13 years

Arm Description

This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.

This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples. If the subject is under the age of 14, an adult lay-user will collect the sample.

Outcomes

Primary Outcome Measures

Usability of Quick Reference Instruction
Primary Endpoints: 1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation.
Usability of Test Kit
Primary Endpoints: 2. Assess the usability of the kit for home use based upon subject evaluation.

Secondary Outcome Measures

Full Information

First Posted
November 18, 2022
Last Updated
February 2, 2023
Sponsor
AccessBio, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05629455
Brief Title
CareSuperb COVID-19 Antigen Test Usability
Official Title
CareSuperb COVID-19 Antigen Home Test Usability Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
November 17, 2022 (Actual)
Primary Completion Date
November 22, 2022 (Actual)
Study Completion Date
November 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AccessBio, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test in Home Use.
Detailed Description
COVID-19 is a contagious respiratory illness, caused by infection with the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This communicable disease is easily transmitted through aerosolized droplets containing the infectious virus. Infections with SARS-CoV-2 can have varying degrees of signs and symptoms, ranging from asymptomatic to severe. Individuals infected with SARS-CoV-2 are believed to be contagious from as early as two days prior to symptom onset to at least ten days after the onset of symptoms. The rapid detection of infections and contacts and the implementation of infection control measures are critical for mitigation of this virus. The CareSuperb COVID-19 Antigen Home Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult lay user-collected anterior nares swab samples from individuals aged 2 to 13 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is an open label study to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test using information from the Quick Reference Instructions (QRI).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
individuals ages 14 years and older
Arm Type
Experimental
Arm Description
This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
Arm Title
individuals aged 2 to 13 years
Arm Type
Experimental
Arm Description
This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples. If the subject is under the age of 14, an adult lay-user will collect the sample.
Intervention Type
Device
Intervention Name(s)
CareSuperb COVID-19 Antigen Home Test Kit
Intervention Description
At home COVID-19 antigen test kit
Primary Outcome Measure Information:
Title
Usability of Quick Reference Instruction
Description
Primary Endpoints: 1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation.
Time Frame
One month
Title
Usability of Test Kit
Description
Primary Endpoints: 2. Assess the usability of the kit for home use based upon subject evaluation.
Time Frame
One month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: An Institutional Review Board (IRB) approved informed consent / assent, if applicable, is signed and dated prior to any study-related activities. Male and female subjects 2 years of age and older. Subject is willing to provide a self-collected nasal swab sample. (If the subject is under the age of 14, an adult lay-user will collect the sample.) Subject agrees to complete all aspects of the study. Exclusion criteria: Subject has a visual impairment that cannot be restored with glasses or contact lenses. Subject has prior medical or laboratory training. Subject uses home diagnostics, e.g., glucose meters, HIV tests. Subject has prior knowledge of their current COVID-19 infection status.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enrique Villa, MD
Organizational Affiliation
L&A Morales Healthcare
Official's Role
Principal Investigator
Facility Information:
Facility Name
L&A Morales Healthcare Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33142
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CareSuperb COVID-19 Antigen Test Usability

We'll reach out to this number within 24 hrs